Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months | Zendy

Stephen J. Thomas | Zendy; Edson Duarte Moreira | Zendy; Nicholas Kitchin | Zendy; Judith Absalon | Zendy; Alejandra Gurtman | Zendy; Stephen Lockhart | Zendy; John L. Perez | Zendy; Gonzalo Pérez Marc | Zendy; Fernando P. Polack | Zendy; Cristiano A. F. Zerbini | Zendy; Ruth Bailey | Zendy; Kena A. Swanson | Zendy; Xia Xu | Zendy; Satrajit Roychoudhury | Zendy; Kenneth Koury | Zendy; Salim Bouguermouh | Zendy; Warren V. Kalina | Zendy; David Cooper | Zendy; Robert W. Frenck | Zendy; Laura L Hammitt | Zendy; Özlem Türeci | Zendy; Haylene Nell | Zendy; Axel Schaefer | Zendy; Serhat Ünal | Zendy; Qi Yang | Zendy; Paul Liberator | Zendy; Dina B Tresnan | Zendy; Susan Mather | Zendy; Philip R. Dormitzer | Zendy; Uǧur Şahin | Zendy; William C. Gruber | Zendy; Kathrin U. Jansen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

Author(s) -

Stephen J. Thomas,

Edson Duarte Moreira,

Nicholas Kitchin,

Judith Absalon,

Alejandra Gurtman,

Stephen Lockhart,

John L. Perez,

Gonzalo Pérez Marc,

Fernando P. Polack,

Cristiano A. F. Zerbini,

Ruth Bailey,

Kena A. Swanson,

Xia Xu,

Satrajit Roychoudhury,

Kenneth Koury,

Salim Bouguermouh,

Warren V. Kalina,

David Cooper,

Robert W. Frenck,

Laura L Hammitt,

Özlem Türeci,

Haylene Nell,

Axel Schaefer,

Serhat Ünal,

Qi Yang,

Paul Liberator,

Dina B Tresnan,

Susan Mather,

Philip R. Dormitzer,

Uǧur Şahin,

William C. Gruber,

Kathrin U. Jansen

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2110345

Subject(s) - medicine , adverse effect , vaccine efficacy , vaccination , placebo , confidence interval , covid-19 , randomized controlled trial , pandemic , clinical trial , immunology , disease , infectious disease (medical specialty) , alternative medicine , pathology

BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly efficacious against coronavirus disease 2019 (Covid-19) and is currently approved, conditionally approved, or authorized for emergency use worldwide. At the time of initial authorization, data beyond 2 months after vaccination were unavailable.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research